OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
GAITHERSBURG, Md., Nov. 01, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, the Company will discuss its financial results for the quarter and year-to-date periods of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: |
| Dial in number: (855) 766-6521 |
| International dial in: (262) 912-6157 |
| Conference ID: 29486767 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/89rbd7rh/lan/en for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
